Kromek Group PLC (AIM:KMK) said the current year has started well with fears over global security sparking a surge in orders for its nuclear-detecting equipment.
Arnab Basu, chief executive, predicted a “strong year-on-year increase in revenue”.
“In advanced imaging, there is increasing widespread need for the early and accurate medical diagnosis facilitated by our CZT-based products,” he said.
“In CBRN (nuclear detection), global insecurity and raised concern over potential nuclear threats continue to underscore the requirement for products such as ours.”
Revenues for the year to end-April 2023 rose by 44% to £17.3mln and Kromek made an underlying profit of £1.7mln in the second half as product sales soared and margins improved.
The AIM-listed group saw record revenues in both medical imaging and nuclear/biothreat detection, with orders rising significantly in both divisions.
Underlying losses reduced to £1mln, though pre-tax losses deepened to £7.3mln (£6.1mln).
Kromek is on track to report an underlying profit (adjusted EBITDA) this year to April 2024, Basu added.